ProTransit Nanotherapy Overview

  • Founded
  • 2013

Founded
  • Status
  • Private

  • Employees
  • 2

Employees
  • Latest Deal Type
  • Series A

  • (Cancelled)
  • Latest Deal Amount
  • $500K

  • Investors
  • 5

ProTransit Nanotherapy General Information

Description

Developer of a proprietary sustained-release nanoparticle delivery system designed to treat conditions with a variety of active ingredients. The company's system contains antioxidant enzymes, where the product helps reduce photoaging caused by free radicals following sun exposure with other topical applications including active ingredients for hair loss and plaque psoriasis, enabling doctors to utilize under-development nanoparticles for the treatment of traumatic brain injury, hypertension, and prevention of skin damage from radiotherapy.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Primary Office
  • 16514 L Street
  • Omaha, NE 68144
  • United States
+1 (608) 000-0000

ProTransit Nanotherapy Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ProTransit Nanotherapy Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series A) $500K 000.00 Cancelled Clinical Trials - Phase 1
5. Grant 01-Jun-2021 00000 00000 Completed Clinical Trials - Phase 1
4. Grant 30-Sep-2020 00000 00000 Completed Pre-Clinical Trials
3. Grant 15-Aug-2018 00000 00000 Completed Pre-Clinical Trials
2. Grant 08-Mar-2017 $1.7M $250K Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 21-Nov-2014 $250K $250K Completed Pre-Clinical Trials
To view ProTransit Nanotherapy’s complete valuation and funding history, request access »

ProTransit Nanotherapy Patents

ProTransit Nanotherapy Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-2996126-A1 Compositions and methods for the treatment of photoaging and other skin conditions Active 25-Aug-2014 0000000000
CA-2996126-C Compositions and methods for the treatment of photoaging and other skin conditions Active 25-Aug-2014 0000000000
US-20170281735-A1 Compositions and methods for the treatment of photoaging and other conditions Active 25-Aug-2014 0000000000
US-10517934-B2 Compositions and methods for the treatment of photoaging and other conditions Active 25-Aug-2014 A61K38/446

ProTransit Nanotherapy Executive Team (2)

Name Title Board Seat Contact Info
Gary Madsen Ph.D Co-Founder, President & Chief Executive Officer
Vinod Labhasetwar Ph.D Co-Founder & Advisor
To view ProTransit Nanotherapy’s complete executive team members history, request access »

ProTransit Nanotherapy Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ProTransit Nanotherapy Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Small Business Innovation Research and Small Business Technology Transfer Programs Government 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
United States Department of Defense Government 000 0000 000000 0
Artesian Beauty Corporation Minority 000 0000 000000 0
Invest Nebraska Accelerator/Incubator Minority 000 0000 000000 0
To view ProTransit Nanotherapy’s complete investors history, request access »